Table of Content

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Metastatic Bone Disease Market

4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Metastatic Bone Disease Market Analysis and Forecast, 2017-2031

5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry

6. Global Metastatic Bone Disease Market Analysis and Forecast, by Treatment
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Treatment, 2017–2031
        6.3.1. Medication
            6.3.1.1. Chemotherapy
            6.3.1.2. Hormone Therapy
            6.3.1.3. Bisphosphonates
            6.3.1.4. Opiate Therapy
            6.3.1.5. Immunotherapy
        6.3.2. Radiation Therapy
        6.3.3. Surgical Intervention
        6.3.4. Tumor Ablation Therapy
    6.4. Market Attractiveness, by Treatment

7. Global Metastatic Bone Disease Market Analysis and Forecast, by Origin of Metastasis
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Origin of Metastasis, 2017–2031
        7.3.1. Breast
        7.3.2. Lung
        7.3.3. Thyroid
        7.3.4. Kidney
        7.3.5. Prostate
        7.3.6. Others
    7.4. Market Attractiveness, by Origin of Metastasis

8. Global Metastatic Bone Disease Market Analysis and Forecast, by Provider Type
    8.1. Introduction and Definitions
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Provider Type, 2017–2031
        8.3.1. OEM
        8.3.2. Non-OEM
    8.4. Market Attractiveness, by Provider Type

9. Global Metastatic Bone Disease Market Analysis and Forecast, by End-user
    9.1. Introduction and Definitions
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by End-user, 2017–2031
        9.3.1. Hospitals
        9.3.2. Specialty Clinics
        9.3.3. Ambulatory Surgical Centers
    9.4. Market Attractiveness, by End-user

10. Global Metastatic Bone Disease Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017–2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness, by Region

11. North America Metastatic Bone Disease Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Treatment, 2017–2031
        11.2.1. Medication
            11.2.1.1. Chemotherapy
            11.2.1.2. Hormone Therapy
            11.2.1.3. Bisphosphonates
            11.2.1.4. Opiate Therapy
            11.2.1.5. Immunotherapy
        11.2.2. Radiation Therapy
        11.2.3. Surgical Intervention
        11.2.4. Tumor Ablation Therapy
    11.3. Market Attractiveness, by Treatment
    11.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
        11.4.1. Breast
        11.4.2. Lung
        11.4.3. Thyroid
        11.4.4. Kidney
        11.4.5. Prostate
        11.4.6. Others
    11.5. Market Attractiveness, by Origin of Metastasis
    11.6. Market Value Forecast, by Provider Type, 2017–2031
        11.6.1. OEM
        11.6.2. Non-OEM
    11.7. Market Attractiveness, by Provider Type
    11.8. Market Value Forecast, by End-user
        11.8.1. Hospitals
        11.8.2. Specialty Clinics
        11.8.3. Ambulatory Surgical Centers
    11.9. Market Attractiveness, by End-user
    11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.10.1. U.S.
        11.10.2. Canada
    11.11. Market Attractiveness Analysis
        11.11.1. By Treatment
        11.11.2. By Origin of Metastasis
        11.11.3. By Provider Type
        11.11.4. By End-user
        11.11.5. By Country

12. Europe Metastatic Bone Disease Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Treatment, 2017–2031
        12.2.1. Medication
            12.2.1.1. Chemotherapy
            12.2.1.2. Hormone Therapy
            12.2.1.3. Bisphosphonates
            12.2.1.4. Opiate Therapy
            12.2.1.5. Immunotherapy
        12.2.2. Radiation Therapy
        12.2.3. Surgical Intervention
        12.2.4. Tumor Ablation Therapy
    12.3. Market Attractiveness, by Treatment
    12.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
        12.4.1. Breast
        12.4.2. Lung
        12.4.3. Thyroid
        12.4.4. Kidney
        12.4.5. Prostate
        12.4.6. Others
    12.5. Market Attractiveness, by Origin of Metastasis
    12.6. Market Value Forecast, by Provider Type, 2017–2031
        12.6.1. OEM
        12.6.2. Non-OEM
    12.7. Market Attractiveness, by Provider Type
    12.8. Market Value Forecast, by End-user, 2017–2031
        12.8.1. Hospitals
        12.8.2. Specialty Clinics
        12.8.3. Ambulatory Surgical Centers
    12.9. Market Attractiveness, by End-user
    12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.10.1. Germany
        12.10.2. U.K.
        12.10.3. France
        12.10.4. Italy
        12.10.5. Spain
        12.10.6. Rest of Europe
    12.11. Market Attractiveness Analysis
        12.11.1. By Treatment
        12.11.2. By Origin of Metastasis
        12.11.3. By Provider Type
        12.11.4. By End-user
        12.11.5. By Country/Sub-region
13. Asia Pacific Metastatic Bone Disease Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Treatment, 2017–2031
        13.2.1. Medication
            13.2.1.1. Chemotherapy
            13.2.1.2. Hormone Therapy
            13.2.1.3. Bisphosphonates
            13.2.1.4. Opiate Therapy
            13.2.1.5. Immunotherapy
        13.2.2. Radiation Therapy
        13.2.3. Surgical Intervention
        13.2.4. Tumor Ablation Therapy
    13.3. Market Attractiveness, by Treatment
    13.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
        13.4.1. Breast
        13.4.2. Lung
        13.4.3. Thyroid
        13.4.4. Kidney
        13.4.5. Prostate
        13.4.6. Others
    13.5. Market Attractiveness, by Origin of Metastasis
    13.6. Market Value Forecast, by Provider Type, 2017–2031
        13.6.1. OEM
        13.6.2. Non-OEM
    13.7. Market Attractiveness, by Provider Type
    13.8. Market Value Forecast, by End-user, 2017–2031
        13.8.1. Hospitals
        13.8.2. Specialty Clinics
        13.8.3. Ambulatory Surgical Centers
    13.9. Market Attractiveness, by End-user
    13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.10.1. China
        13.10.2. Japan
        13.10.3. India
        13.10.4. Australia & New Zealand
        13.10.5. Rest of Asia Pacific
    13.11. Market Attractiveness Analysis
        13.11.1. By Treatment
        13.11.2. By Origin of Metastasis
        13.11.3. By Provider Type
        13.11.4. By End-user
        13.11.5. By Country/Sub-region
14. Latin America Metastatic Bone Disease Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Treatment, 2017–2031
        14.2.1. Medication
            14.2.1.1. Chemotherapy
            14.2.1.2. Hormone Therapy
            14.2.1.3. Bisphosphonates
            14.2.1.4. Opiate Therapy
            14.2.1.5. Immunotherapy
        14.2.2. Radiation Therapy
        14.2.3. Surgical Intervention
        14.2.4. Tumor Ablation Therapy
    14.3. Market Attractiveness, by Treatment
    14.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
        14.4.1. Breast
        14.4.2. Lung
        14.4.3. Thyroid
        14.4.4. Kidney
        14.4.5. Prostate
        14.4.6. Others
    14.5. Market Attractiveness, by Origin of Metastasis
    14.6. Market Value Forecast, by Provider Type, 2017–2031
        14.6.1. OEM
        14.6.2. Non-OEM
    14.7. Market Attractiveness, by Provider Type
    14.8. Market Value Forecast, by End-user, 2017–2031
        14.8.1. Hospitals
        14.8.2. Specialty Clinics
        14.8.3. Ambulatory Surgical Centers
    14.9. Market Attractiveness, by End-user
    14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.10.1. Brazil
        14.10.2. Mexico
        14.10.3. Rest of Latin America
    14.11. Market Attractiveness Analysis
        14.11.1. By Treatment
        14.11.2. By Origin of Metastasis
        14.11.3. By Provider Type
        14.11.4. By End-user
        14.11.5. By Country/Sub-region

15. Middle East & Africa Metastatic Bone Disease Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Treatment, 2017–2031
        15.2.1. Medication
            15.2.1.1. Chemotherapy
            15.2.1.2. Hormone Therapy
            15.2.1.3. Bisphosphonates
            15.2.1.4. Opiate Therapy
            15.2.1.5. Immunotherapy
        15.2.2. Radiation Therapy
        15.2.3. Surgical Intervention
        15.2.4. Tumor Ablation Therapy
    15.3. Market Attractiveness, by Treatment
    15.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
        15.4.1. Breast
        15.4.2. Lung
        15.4.3. Thyroid
        15.4.4. Kidney
        15.4.5. Prostate
        15.4.6. Others
    15.5. Market Attractiveness, by Origin of Metastasis
    15.6. Market Value Forecast, by Provider Type, 2017–2031
        15.6.1. OEM
        15.6.2. Non-OEM
    15.7. Market Attractiveness, by Provider Type
    15.8. Market Value Forecast, by End-user, 2017–2031
        15.8.1. Hospitals
        15.8.2. Specialty Clinics
        15.8.3. Ambulatory Surgical Centers
    15.9. Market Attractiveness, by End-user
    15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
        15.10.1. GCC Countries
        15.10.2. South Africa
        15.10.3. Rest of Middle East & Africa
    15.11. Market Attractiveness Analysis
        15.11.1. By Treatment
        15.11.2. By Origin of Metastasis
        15.11.3. By Provider Type
        15.11.4. By End-user
        15.11.5. By Country/Sub-region

16. Competition Landscape
    16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. Amgen, Inc.
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Merck & Co., Inc.
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. F. Hoffmann-La Roche Ltd.
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Novartis AG
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Eli Lilly and Company
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Bayer AG
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Fresenius Kabi AG
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Boston Scientific Corporation
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Medtronic
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview



List of Figures

List of Figures

Figure 01: Global Metastatic Bone Disease Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031

Figure 02: Global Metastatic Bone Disease Market Revenue (US$ Mn), by Treatment, 2022

Figure 03: Global Metastatic Bone Disease Market Value Share, by Treatment, 2022

Figure 04: Global Metastatic Bone Disease Market Revenue (US$ Mn), by Origin of Metastasis, 2022

Figure 05: Global Metastatic Bone Disease Market Value Share, by Origin of Metastasis, 2022

Figure 06: Global Metastatic Bone Disease Market Revenue (US$ Mn), by Provider Type, 2022

Figure 07: Global Metastatic Bone Disease Market Value Share, by Provider Type, 2022

Figure 08: Global Metastatic Bone Disease Market Value Share, by End-user, 2022

Figure 09: Global Metastatic Bone Disease Market Value Share, by End-user, 2022

Figure 10: Global Metastatic Bone Disease Market Value Share, by Region, 2022

Figure 11: Global Metastatic Bone Disease Market Value (US$ Mn) Forecast, 2017–2031

Figure 12: Global Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031

Figure 13: Global Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023-2031

Figure 14: Global Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031

Figure 15: Global Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031

Figure 16: Global Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031

Figure 17: Global Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031

Figure 18: Global Metastatic Bone Disease Market Revenue (US$ Mn), by End-user, 2022

Figure 19: Global Metastatic Bone Disease Market Value Share, by End-user, 2022

Figure 20: Global Metastatic Bone Disease Market Value Share Analysis, by Region, 2022 and 2031

Figure 21: Global Metastatic Bone Disease Market Attractiveness Analysis, by Region, 2023-2031

Figure 22: North America Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 23: North America Metastatic Bone Disease Market Attractiveness Analysis, by Country, 2023–2031

Figure 24: North America Metastatic Bone Disease Market Value Share Analysis, by Country, 2022 and 2031

Figure 25: North America Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031

Figure 26: North America Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031

Figure 27: North America Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031

Figure 28: North America Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031

Figure 29: North America Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023–2031

Figure 30: North America Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023–2031

Figure 31: North America Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023–2031

Figure 32: North America Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023–2031

Figure 33: Europe Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 34: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 35: Europe Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 36: Europe Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031

Figure 37: Europe Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031

Figure 38: Europe Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031

Figure 39: Europe Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031

Figure 40: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023–2031

Figure 41: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023–2031

Figure 42: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023–2031

Figure 43: Europe Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023–2031

Figure 44: Asia Pacific Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

Figure 45: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 46: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 47: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031

Figure 48: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031

Figure 49: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031

Figure 50: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031

Figure 51: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2017–2031

Figure 52: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023–2031

Figure 53: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023–2031

Figure 54: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023–2031

Figure 55: Latin America Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 56: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 57: Latin America Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 58: Latin America Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031

Figure 59: Latin America Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031

Figure 60: Latin America Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031

Figure 61: Latin America Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031

Figure 62: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023–2031

Figure 63: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023–2031

Figure 64: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023–2031

Figure 65: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023–2031

Figure 66: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 67: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 68: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 69: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031

Figure 70: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031

Figure 71: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031

Figure 72: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031

Figure 73: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023–2031

Figure 74: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023–2031

Figure 75: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023–2031

Figure 76: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023–2031

List of Tables

List of Tables

Table 01: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

Table 02: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017–2031

Table 03: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017–2031

Table 04: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 05: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 07: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

Table 08: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017–2031

Table 09: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017–2031

Table 10: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 11: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

Table 13: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017–2031

Table 14: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017–2031

Table 15: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 16: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

Table 18: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017–2031

Table 19: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017–2031

Table 20: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

Table 23: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017–2031

Table 24: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017–2031

Table 25: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 26: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 27: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

Table 28: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017–2031

Table 29: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017–2031

Table 30: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017–2031